2.50
Hdl Handle:
http://hdl.handle.net/10547/578806
Title:
PASD1: a promising target for the immunotherapy of haematological malignancies
Authors:
Khan, Ghazala; Denniss, Frances; Mills, Ken; Pulford, Karen; Guinn, Barbara-Ann
Abstract:
In general, there is a lack of good immunotherapy targets within the spectrum of haematological malignancies. However haematopoietic stem cell transplants and continuing antigen discovery have allowed further insight into how further improvements in outcomes for patients might be achieved. Most patients with haematological malignancies can be treated with conventional therapies such as radio- and chemotherapy and will attain first remission. However the removal of residual diseased cells is essential to prevent relapse and its associated high mortality. PASD1 is one of the most tissue restricted cancer-testis (CT) antigens with expression limited to primary spermatagonia in healthy tissue. However, characterisation of PASD1 expression in cancers has been predominantly focussed on haematological malignancies where the inappropriate expression of PASD1 was first identified. PASD1 has one of the highest frequencies of expression of all CT antigens in acute myeloid leukaemia, with some suggestion of its role as a biomarker in diffuse large B-cell lymphoma. Here we describe the characterisation of the function and expression patterns of PASD1 in cell lines and primary tissues. Development of DNA vaccines targeting PASD1 epitopes demonstrate effective ex vivo T-cell responses in terms of IFNγ secretion and tumour cell killing. Of particular note these vaccines have led to the destruction of cells which process and present endogenous PASD1 indicating that effectively primed CTLs could kill PASD1-positive tumour cells.
Affiliation:
University of Bedfordshire
Citation:
Khan, G., Denniss, F., Mills, K.I., Pulford, K. & Guinn, B.A. (2013) 'PASD1: a promising target for the immunotherapy of haematological malignancies'. Journal of Genetic Syndromes & Gene Therapy, 4:186.
Publisher:
OMICS International
Journal:
Journal of Genetic Syndromes & Gene Therapy
Issue Date:
Oct-2013
URI:
http://hdl.handle.net/10547/578806
DOI:
10.4172/2157-7412.1000186
Additional Links:
http://www.omicsonline.org/pasd-a-promising-target-for-the-immunotherapy-of-haematological-malignancies-2157-7412.1000186.php?aid=19315
Type:
Article
Language:
en
ISSN:
2157-7412
Appears in Collections:
Biomedicine and Nutrition Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorKhan, Ghazalaen
dc.contributor.authorDenniss, Francesen
dc.contributor.authorMills, Kenen
dc.contributor.authorPulford, Karenen
dc.contributor.authorGuinn, Barbara-Annen
dc.date.accessioned2015-09-28T09:08:23Zen
dc.date.available2015-09-28T09:08:23Zen
dc.date.issued2013-10en
dc.identifier.citationKhan, G., Denniss, F., Mills, K.I., Pulford, K. & Guinn, B.A. (2013) 'PASD1: a promising target for the immunotherapy of haematological malignancies'. Journal of Genetic Syndromes & Gene Therapy, 4:186.en
dc.identifier.issn2157-7412en
dc.identifier.doi10.4172/2157-7412.1000186en
dc.identifier.urihttp://hdl.handle.net/10547/578806en
dc.description.abstractIn general, there is a lack of good immunotherapy targets within the spectrum of haematological malignancies. However haematopoietic stem cell transplants and continuing antigen discovery have allowed further insight into how further improvements in outcomes for patients might be achieved. Most patients with haematological malignancies can be treated with conventional therapies such as radio- and chemotherapy and will attain first remission. However the removal of residual diseased cells is essential to prevent relapse and its associated high mortality. PASD1 is one of the most tissue restricted cancer-testis (CT) antigens with expression limited to primary spermatagonia in healthy tissue. However, characterisation of PASD1 expression in cancers has been predominantly focussed on haematological malignancies where the inappropriate expression of PASD1 was first identified. PASD1 has one of the highest frequencies of expression of all CT antigens in acute myeloid leukaemia, with some suggestion of its role as a biomarker in diffuse large B-cell lymphoma. Here we describe the characterisation of the function and expression patterns of PASD1 in cell lines and primary tissues. Development of DNA vaccines targeting PASD1 epitopes demonstrate effective ex vivo T-cell responses in terms of IFNγ secretion and tumour cell killing. Of particular note these vaccines have led to the destruction of cells which process and present endogenous PASD1 indicating that effectively primed CTLs could kill PASD1-positive tumour cells.en
dc.language.isoenen
dc.publisherOMICS Internationalen
dc.relation.urlhttp://www.omicsonline.org/pasd-a-promising-target-for-the-immunotherapy-of-haematological-malignancies-2157-7412.1000186.php?aid=19315en
dc.subjectPASDen
dc.subjectimmunotherapyen
dc.subjectcanceren
dc.subjecttumour antigenen
dc.subjectcancer-testis antigenen
dc.subjectC550 Immunologyen
dc.titlePASD1: a promising target for the immunotherapy of haematological malignanciesen
dc.typeArticleen
dc.contributor.departmentUniversity of Bedfordshireen
dc.identifier.journalJournal of Genetic Syndromes & Gene Therapyen
All Items in UOBREP are protected by copyright, with all rights reserved, unless otherwise indicated.